Abstract LB-153: Therapeutic effect of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinaseM2 and mechanistic target of rapamycin complex 1 pathways

2019 ◽  
Author(s):  
Hyung Sik Kim ◽  
Kyeong Seok Kim
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Therapeutic Effect ◽  
Renal Cell ◽  
Target Of Rapamycin ◽  
Advanced Renal Cell Carcinoma ◽  
Mechanistic Target Of Rapamycin ◽  
Dual Targeting

scholarly journals Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives

2021 ◽  
Vol 9 ◽  
Author(s):  
Seraina Faes ◽  
Nicolas Demartines ◽  
Olivier Dormond
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Inhibitors ◽  
Target Of Rapamycin ◽  
Cancer Cell Proliferation ◽  
Hypoxia Inducible Factors ◽  
Mtor Signaling Pathway ◽  
Mechanistic Target Of Rapamycin

Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies.

Sign in / Sign up

Export Citation Format

Share Document